Elaprase is a prescription medicine designed to improve walking ability in patients aged 5 years and older with Hunter syndrome. It has also been shown to reduce spleen size in patients aged 16 months to 5 years, although it does not improve disease-related symptoms or long-term clinical results in this age group.
However, it is important to note that Elaprase carries the risk of serious allergic reactions, including life-threatening anaphylactic reactions, which can occur during and up to 24 hours after treatment. Patients should be closely monitored during and after treatment, and healthcare teams should be prepared to manage any allergic reactions that may arise.
Generated from the website